Perrigo To Present At The 20th Annual Oppenheimer Consumer Growth & E-Commerce Virtual Conference

On June 2, 2020 Perrigo Company plc (NYSE; TASE: PRGO) reported that President and CEO Murray S. Kessler will present further details on the Company’s consumer growth strategy along with a general update on the business at the 20th Annual Oppenheimer Consumer Growth and E-Commerce Virtual Conference at 2:00 PM EDT on Wednesday, June 17, 2020 (Press release, Perrigo Company, JUN 2, 2020, View Source [SID1234560757]). Interested parties can access the presentation webcast at View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


CASI Pharmaceuticals To Present At The Jefferies 2020 Healthcare Conference

On June 2, 2020 CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, reported that Dr. Wei-Wu He, Chairman & CEO will present an overview of the company and provide a business update at the Jefferies 2020 Healthcare Conference on Thursday, June 4, 2020, at 4:00 p.m. ET (Press release, CASI Pharmaceuticals, JUN 2, 2020, View Source [SID1234560774]). The conference will be held in a virtual meeting format.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the live webcast presentation, or the subsequent archived recording, please visit the "Investor Center" section of the CASI website at www.casipharmaceuticals.com.

VBL Presents Positive Interim Data from the OVAL Phase 3 Pivotal Study in Ovarian Cancer at the ASCO20 Annual Meeting, Showing 58% or Higher Objective Response Rate

On June 1, 2020 VBL Therapeutics (Nasdaq: VBLT), reported the presentation of the positive outcome of pre-planned interim analysis results from the OVAL Phase 3 pivotal clinical trial in platinum-resistant ovarian cancer at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2020 virtual annual meeting (Press release, VBL Therapeutics, JUN 1, 2020, View Source [SID1234558783]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The analysis compared the CA-125 objective response rate (ORR) according to GCIG criteria in the treatment and control arms among the first 60 evaluable patients. The CA-125 ORR in those patients was 53%. Assuming a balanced randomization, the response rate in the treatment arm (VB-111 in addition to weekly paclitaxel) was 58% or higher. In patients who had post-dosing fever, which is a marker for VB-111 treatment, the response rate was 69%.

The CA-125 response rate observed in the Phase 3 interim analysis is at least as good as the response rate seen in the prior Phase 2 study, which enrolled a similar patient population and showed overall survival benefit. In the previously reported Phase 2 study of VB-111 in platinum resistant ovarian cancer, 58% of the patients treated with VB-111 and paclitaxel demonstrated a CA-125 response. Those patients with a CA-125 response demonstrated a median overall survival of 808 days, versus 351 days for those patients without a CA-125 response.

"The OVAL interim data are very encouraging as they demonstrate the potential benefit of VB-111 over standard-of-care in a randomized-controlled setting," said Tami Rachmilewitz, M.D., Vice President Clinical Development of VBL Therapeutics. "With over 25% of the patients already enrolled in the study, we look forward to further advancing the OVAL study by expansion to Europe and Japan later this year."

For VBL’s presentation at ASCO (Free ASCO Whitepaper) see: Link

About the OVAL (VB-111-701/GOG-3018) study (NCT03398655)
OVAL is an international Phase 3 randomized, double-blind, placebo-controlled potential registration clinical trial that compares a combination of VB-111 and paclitaxel to placebo plus paclitaxel, in patients with platinum-resistant ovarian cancer. The study is planned to enroll approximately 400 patients. OVAL is conducted in collaboration with the GOG Foundation, Inc., an independent international non-profit organization with the purpose of promoting excellence in the quality and integrity of clinical and basic scientific research in the field of gynecologic malignancies.

About VB-111 (ofranergene obadenovec)
VB-111 is a first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors. VB-111 is a unique biologic agent that uses a dual mechanism to target solid tumors. Its mechanism combines blockade of tumor vasculature with an anti-tumor immune response. VB-111 is administered as an IV infusion once every 6-8 weeks. It has been observed to be well-tolerated in >300 cancer patients and demonstrated activity signals in an "all comers" Phase 1 trial as well as in three tumor-specific Phase 2 studies. VB-111 has received an Orphan Designation for the treatment of ovarian cancer from the European Commission. VB-111 has also received orphan drug designation in both the US and Europe, and fast track designation in the US for prolongation of survival in patients with rGBM. VB-111 successfully demonstrated proof-of-concept and survival benefit in Phase 2 clinical trials in radioiodine-refractory thyroid cancer and recurrent platinum-resistant ovarian cancer (NCT01711970).

Aeglea BioTherapeutics to Present at BIO Digital 2020

On June 1, 2020 Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, reported it will provide a corporate overview at BIO Digital being held virtually June 8-12, 2020 (Press release, Aeglea BioTherapeutics, JUN 1, 2020, View Source [SID1234560724]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details

Date: June 8-12, 2020
Presenter: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea’s president and chief executive officer
Location: View Source

The presentation will be available for download on the Presentations & Events section of the Company’s website and also will be available on-demand to registered participants of BIO Digital at View Source/sessions/620997.

BERG Presents Results of Phase 1 Clinical Study in Glioblastoma at 2020 American Society of Clinical Oncology (ASCO) Meeting

On June 1, 2020 BERG, a clinical-stage biotech company that uses Artificial Intelligence (AI) to research diseases and develop innovative treatments, reported results from a Phase 1 clinical study of its investigational drug, BPM 31510 (novel ubidecarenone formulation) in glioblastoma (GBM) (Press release, Berg, JUN 1, 2020, View Source [SID1234560741]). The study, presented at the 2020 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting (ASCO) (Free ASCO Whitepaper), highlights safety, tolerability and the impact of BPM 31510-IV influence on metabolism in patients, supporting planned Phase 2 clinical development.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"At BERG, we understand the toll cancer takes not only on a patient, but also their loved ones, and we want to lead in the battle to fight the disease," said Dr. Niven R. Narain, BERG Co-founder, President and Chief Executive Officer. "BPM 31510 is a unique therapeutic modality targeting cell metabolism that is consistent with our proprietary Interrogative Biology platform. We are excited at the opportunities the findings will have in refining clinical development among multiple cancer indications, especially in brain cancers."

GBM is a destructive type of brain cancer often acknowledged for its steep morbidity and mortality rates. There are few effective treatment options available in the marketplace, thus substantiating the urgent need for novel therapeutic approaches to improve outcomes for this disease. BPM 31510 is a unique therapeutic modality which specifically targets cell metabolism and shifts the cancer’s glycolytic dependency toward mitochondrial oxidative phosphorylation. When applied, it induces oxidative stress and causes cell death, specifically of cancer cells. BPM 31510 serves as particularly relevant indication for GBM’s glycolytic dependency.

The study was led by Seema Nagpal, M.D. Clinical Associated Professor of Neurology & Neurological Sciences, and Lawrence Recht, M.D., Professor of Neurology & Neurological Sciences, both of Stanford University School of Medicine, with other Stanford Medicine researchers and in collaboration with BERG.

Details of the BERG presentation:
This Poster is available to registered 2020 ASCO (Free ASCO Whitepaper) Virtual Scientific Program attendees and can be viewed at:
View Source

In its commitment to serve patients afflicted with cancer, BERG has collaborated on other projects with leading institutions, like MD Anderson Cancer Institute (clinical trials) and Harvard/BIDMC (Project Survival), among others.